公开(公告)号：WO2021263205A1

公开(公告)日：2021-12-30

申请号：PCT/US2021/039248

申请日：2021-06-25

Applicant: CV6 THERAPEUTICS (NI) LIMITED

Inventor： MULLIGAN, Karl Andrew ,  WILSON, Peter Michael ,  WILSON, Melissa J LaBonte ,  LADNER, Robert D.

IPC: A61K31/4164 ,  A61K31/4168 ,  A61K31/506 ,  A61K31/4178 ,  A61K31/497 ,  A61K31/4439 ,  A61K31/501 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/496 ,  A61K31/433 ,  A61K31/5377 ,  A61K31/41 ,  A61K31/422 ,  A61K31/4192 ,  A61K31/4184 ,  A61K31/541 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61K31/7072 ,  A61K45/06 ,  A61K35/17 ,  A61K38/12 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/212 ,  A61K39/39558 ,  C07K16/2818

Abstract: Provided herein are deoxyuridine triphosphatase (dUTPase) inhibitors for use in methods of enhancing a therapeutic efficacy of an immunotherapy agent in a subject in need thereof and in methods of treating cancer in a subject in need thereof, the methods comprising administering to the subject an effective amount of a deoxyuridine triphosphatase (dUTPase) inhibitor and the immunotherapy agent, and optionally further comprising administering to the subject one or more selected from an effective amount of an inhibitor of thymidylate biosynthesis, and an effective amount of an anthracycline or other topoisomerase II inhibitor.